The association of miR-126-3p, miR-126-5p and miR-664-3p
expression profiles with outcomes of patients with metastatic
colorectal cancer treated with bevacizumab

J 2017

The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab

FIALA, O., P. PITULE, P. HOSEK, V. LISKA, O. SOREJS et. al.

Basic information

Original name

The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab

Authors

FIALA, O. (203 Czech Republic), P. PITULE (203 Czech Republic), P. HOSEK (203 Czech Republic), V. LISKA (203 Czech Republic), O. SOREJS (203 Czech Republic), J. BRUHA (203 Czech Republic), O. VYCITAL (203 Czech Republic), T. BUCHLER (203 Czech Republic), Alexandr POPRACH (203 Czech Republic, guarantor, belonging to the institution), O. TOPOLCAN (203 Czech Republic) and J. FINEK (203 Czech Republic)

Edition

Tumor Biology, Dordrecht, Springer, 2017, 1010-4283

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.650 in 2016

RIV identification code

RIV/00216224:14110/17:00098712

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1177/1010428317709283

UT WoS

000407152800001

Keywords in English

Colorectal cancer; bevacizumab; chemotherapy; microRNA; miR-126-3p; miR-126-5p; miR-664-3p

Abstract

V originále

MicroRNAs regulate the expression of genes involved in several important cancer-related processes including cell adhesion, proliferation, and tumour angiogenesis. Bevacizumab is routinely used in the treatment of patients with metastatic colorectal cancer, but, so far, no reliable biomarker predicting response to bevacizumab has been established. The aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. The study included 63 patients. For the assessment of microRNA expression, gene-specific TaqMan assays were used. The median progression-free survival and overall survival for patients with low tumour expression of miR-126-3p were 8.8 and 20.6 months versus 13.5 months and median overall survival was not reached for patients with high expression (p = 0.0064 and p = 0.0027), respectively. The median progression-free survival and overall survival for patients with low tumour expression of miR-126-5p were 9.0 and 22.2 months versus 12.0 and 23.4 months for patients with high expression (p = 0.2113 and 0.6858), respectively. The median progression-free survival and overall survival for patients with low tumour expression of miR-664-3p were 9.1 and 22.5 months versus 8.8 and 23.4 months for patients with high expression (p = 0.2542 and p = 0.1922), respectively. The multivariable Cox proportional hazards model revealed that miR-126-3p expression was significantly associated with progression-free survival (hazard ratio = 0.28, p = 0.0053) and also with overall survival (hazard ratio = 0.18, p = 0.0046). In conclusion, the results of this study suggest that the expression of miR-126-3p in the tumour tissue was associated with outcome of metastatic colorectal cancer patients treated with bevacizumab.

Citovat

FIALA, O., P. PITULE, P. HOSEK, V. LISKA, O. SOREJS, J. BRUHA, O. VYCITAL, T. BUCHLER, Alexandr POPRACH, O. TOPOLCAN and J. FINEK. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. Tumor Biology. Dordrecht: Springer, 2017, vol. 39, No 7, p. 1-9. ISSN 1010-4283. Available from: https://dx.doi.org/10.1177/1010428317709283.

@article{1398908,
   author = {Fiala, O. and Pitule, P. and Hosek, P. and Liska, V. and Sorejs, O. and Bruha, J. and Vycital, O. and Buchler, T. and Poprach, Alexandr and Topolcan, O. and Finek, J.},
   article_location = {Dordrecht},
   article_number = {7},
   doi = {http://dx.doi.org/10.1177/1010428317709283},
   keywords = {Colorectal cancer; bevacizumab; chemotherapy; microRNA; miR-126-3p; miR-126-5p; miR-664-3p},
   language = {eng},
   issn = {1010-4283},
   journal = {Tumor Biology},
   title = {The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab},
   volume = {39},
   year = {2017}
}

TY  - JOUR
ID  - 1398908
AU  - Fiala, O. - Pitule, P. - Hosek, P. - Liska, V. - Sorejs, O. - Bruha, J. - Vycital, O. - Buchler, T. - Poprach, Alexandr - Topolcan, O. - Finek, J.
PY  - 2017
TI  - The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab
JF  - Tumor Biology
VL  - 39
IS  - 7
SP  - 1-9
EP  - 1-9
PB  - Springer
SN  - 10104283
KW  - Colorectal cancer
KW  - bevacizumab
KW  - chemotherapy
KW  - microRNA
KW  - miR-126-3p
KW  - miR-126-5p
KW  - miR-664-3p
N2  - MicroRNAs regulate the expression of genes involved in several important cancer-related processes including cell adhesion, proliferation, and tumour angiogenesis. Bevacizumab is routinely used in the treatment of patients with metastatic colorectal cancer, but, so far, no reliable biomarker predicting response to bevacizumab has been established. The aim of our retrospective study was to evaluate the association of miR-126-3p, miR-126-5p and miR-664-3p tumour expression levels with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. The study included 63 patients. For the assessment of microRNA expression, gene-specific TaqMan assays were used. The median progression-free survival and overall survival for patients with low tumour expression of miR-126-3p were 8.8 and 20.6 months versus 13.5 months and median overall survival was not reached for patients with high expression (p = 0.0064 and p = 0.0027), respectively. The median progression-free survival and overall survival for patients with low tumour expression of miR-126-5p were 9.0 and 22.2 months versus 12.0 and 23.4 months for patients with high expression (p = 0.2113 and 0.6858), respectively. The median progression-free survival and overall survival for patients with low tumour expression of miR-664-3p were 9.1 and 22.5 months versus 8.8 and 23.4 months for patients with high expression (p = 0.2542 and p = 0.1922), respectively. The multivariable Cox proportional hazards model revealed that miR-126-3p expression was significantly associated with progression-free survival (hazard ratio = 0.28, p = 0.0053) and also with overall survival (hazard ratio = 0.18, p = 0.0046). In conclusion, the results of this study suggest that the expression of miR-126-3p in the tumour tissue was associated with outcome of metastatic colorectal cancer patients treated with bevacizumab.
ER  -

FIALA, O., P. PITULE, P. HOSEK, V. LISKA, O. SOREJS, J. BRUHA, O. VYCITAL, T. BUCHLER, Alexandr POPRACH, O. TOPOLCAN and J. FINEK. The association of miR-126-3p, miR-126-5p and miR-664-3p expression profiles with outcomes of patients with metastatic colorectal cancer treated with bevacizumab. \textit{Tumor Biology}. Dordrecht: Springer, 2017, vol.~39, No~7, p.~1-9. ISSN~1010-4283. Available from: https://dx.doi.org/10.1177/1010428317709283.

Detailed Information on Publication Record